Shopping Cart 0
Cart Subtotal
USD 0

NanoCarrier Co Ltd (4571) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

NanoCarrier Co Ltd (NanoCarrier) is a drug development company that develops and produces pharmaceuticals using micellar nanoparticles technology. The company's pipeline products include NC-6004, NC-4016, NC-6300, VB-111, NC-6201 and NK105. It offers siRNA micelle, protein micelle, DACH-platin micelle, paclitaxel micelle, pH-sensitive micelle, sensor linked micelle and docetaxel micelle. NanoCarrier's NC-6004 is used for the treatment for pancreatic cancer, head and neck cancer, bladder cancer, and biliary tract cancer. The company's VB-111 is used for the treatment of recurrent glioblastoma, ovarian cancer and thyroid cancer. Its micellar nanoparticle technology is also used in developing cosmetics and healthcare products. The company operates its office in Tokyo, Japan. NanoCarrier is headquartered in Kashiwa, Japan.

NanoCarrier Co Ltd (4571)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

NanoCarrier Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

NanoCarrier Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10

NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

AccuRna Raises USD4.7 Million in Venture Financing 13

Partnerships 14

NanoCarrier to Enter into Agreement with Ceolia Pharma 14

NanoCarrier Enters into Agreement with JCR Pharma 15

NanoCarrier Enters into Research Agreement with University of Utah 16

NanoCarrier will Enter into Research Agreement with TPG Biologics 17

NanoCarrier Enters Into R&D Agreement With Shin-Etsu Chemical For Cancer Treatment 18

NanoCarrier and LFB Biotechnologies Enter into Research Agreement 19

NanoCarrier Extends Research Agreement With Kyoto University 20

NanoCarrier Enters Into Co-Development Agreement With Eisai 21

Licensing Agreements 22

Nanocarrier Enters into Licensing Agreement with Orient Europharma 22

Nanocarrier Enters into Licensing Agreement with VBL Therapeutics 23

TODAI TLO Enters into Licensing Agreement with NanoCarrier 24

NanoCarrier Enters into Licensing Agreement with AccuRna 25

NanoCarrier Enters into Licensing Agreement with Eisai 26

NanoCarrier Enters Into Licensing Agreement With NOF For Nucleotide Delivery Polymer 27

Equity Offering 28

NanoCarrier to Raise USD11.3 Million in Private Placement of Shares 28

NanoCarrier Agrees to Invest in Tocagen 29

NanoCarrier Completes Private Placement Of Shares For USD 4.3 Million 30

NanoCarrier Completes Public Offering Of Shares For USD 89 Million 31

NanoCarrier Completes Private Placement Of Shares Upon Exercise Of Warrants For USD 20 Million 32

NanoCarrier Completes Private Placement Of Shares For USD 8.6 Million 33

Debt Offering 34

NanoCarrier Completes Private Placement Of First Series Bonds For USD 10.8 Million 34

NanoCarrier Completes Private Placement Of Second Series Bonds For USD 11 Million 35

Acquisition 36

NanoCarrier to Acquire 5.23% Stake in Gene Techno Science for USD11.4 Million 36

NanoCarrier Co Ltd-Key Competitors 37

NanoCarrier Co Ltd-Key Employees 38

NanoCarrier Co Ltd-Locations And Subsidiaries 39

Head Office 39

Other Locations & Subsidiaries 39

Recent Developments 40

Strategy And Business Planning 40

Aug 16, 2017: Establishment of US Subsidiary of NanoCarrier and Employment of Managing Director 40

Product News 41

10/27/2017: NanoCarrier Announces Results of a Phase Ib Clinical Study of NC-6004 in the US 41

01/05/2017: Notice on the Initiation of the Phase I/II Clinical Study on NC-6300 (Epirubicin Micelle) for Patients with Rare Cancers in the U.S. 42

Clinical Trials 43

Aug 01, 2017: Notice of Orphan Drug Designation of NC-6004 (biliary tract cancer) by the U.S. FDA 43

Apr 20, 2017: Notice of Resume of Phase III Clinical Study on NC-6004 for Patients with Pancreatic Cancer 44

Feb 23, 2017: Publication on Results of Phase I Clinical Study of NC-6004 Conducted in Japan 45

Feb 09, 2017: Notice Concerning the Progress of the Phase III Clinical Study on NC-6004 for Patients with Pancreatic Cancer 46

Other Significant Developments 47

Jan 17, 2018: NanoCarrier in discussions for Business Alliance with CEOLIA 47

Appendix 48

Methodology 48

About GlobalData 48

Contact Us 48

Disclaimer 48


List Of Figure

List of Figures

NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

NanoCarrier Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

NanoCarrier Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

NanoCarrier Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

NanoCarrier Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10

NanoCarrier Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

AccuRna Raises USD4.7 Million in Venture Financing 13

NanoCarrier to Enter into Agreement with Ceolia Pharma 14

NanoCarrier Enters into Agreement with JCR Pharma 15

NanoCarrier Enters into Research Agreement with University of Utah 16

NanoCarrier will Enter into Research Agreement with TPG Biologics 17

NanoCarrier Enters Into R&D Agreement With Shin-Etsu Chemical For Cancer Treatment 18

NanoCarrier and LFB Biotechnologies Enter into Research Agreement 19

NanoCarrier Extends Research Agreement With Kyoto University 20

NanoCarrier Enters Into Co-Development Agreement With Eisai 21

Nanocarrier Enters into Licensing Agreement with Orient Europharma 22

Nanocarrier Enters into Licensing Agreement with VBL Therapeutics 23

TODAI TLO Enters into Licensing Agreement with NanoCarrier 24

NanoCarrier Enters into Licensing Agreement with AccuRna 25

NanoCarrier Enters into Licensing Agreement with Eisai 26

NanoCarrier Enters Into Licensing Agreement With NOF For Nucleotide Delivery Polymer 27

NanoCarrier to Raise USD11.3 Million in Private Placement of Shares 28

NanoCarrier Agrees to Invest in Tocagen 29

NanoCarrier Completes Private Placement Of Shares For USD 4.3 Million 30

NanoCarrier Completes Public Offering Of Shares For USD 89 Million 31

NanoCarrier Completes Private Placement Of Shares Upon Exercise Of Warrants For USD 20 Million 32

NanoCarrier Completes Private Placement Of Shares For USD 8.6 Million 33

NanoCarrier Completes Private Placement Of First Series Bonds For USD 10.8 Million 34

NanoCarrier Completes Private Placement Of Second Series Bonds For USD 11 Million 35

NanoCarrier to Acquire 5.23% Stake in Gene Techno Science for USD11.4 Million 36

NanoCarrier Co Ltd, Key Competitors 37

NanoCarrier Co Ltd, Key Employees 38

NanoCarrier Co Ltd, Other Locations 39

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

NanoCarrier Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.